GSK PLC Sponsored ADR (NYSE:GSK) Stock Rated “Hold” by Sell-Side Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been given an average recommendation of “Hold” by the nineteen research firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $55.33.

GSK has been the topic of several recent research reports. Citigroup initiated coverage on GSK in a research report on Friday, July 24th. They issued a “neutral” rating on the stock. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. The Goldman Sachs Group restated a “neutral” rating on shares of GSK in a report on Monday, June 29th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Finally, Barclays reiterated a “sell” rating on shares of GSK in a report on Monday, September 7th.

Institutional Trading of GSK

A number of large investors have recently made changes to their positions in GSK. Bogart Wealth LLC lifted its stake in shares of GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after acquiring an additional 200 shares during the last quarter. Natural Investments LLC boosted its holdings in GSK by 2.8% during the 2nd quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock valued at $405,000 after acquiring an additional 211 shares during the period. Flagship Harbor Advisors LLC boosted its holdings in GSK by 2.1% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,089 shares of the pharmaceutical company’s stock valued at $486,000 after acquiring an additional 211 shares during the period. Grove Bank & Trust grew its position in GSK by 3.8% in the 3rd quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company’s stock valued at $282,000 after acquiring an additional 215 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. grew its position in GSK by 3.7% in the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 6,185 shares of the pharmaceutical company’s stock valued at $298,000 after acquiring an additional 223 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.7%

Shares of NYSE GSK opened at $51.10 on Tuesday. GSK has a fifty-two week low of $42.88 and a fifty-two week high of $61.69. The firm has a market capitalization of $103.37 billion, a P/E ratio of 15.98, a P/E/G ratio of 2.28 and a beta of 0.33. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The company’s 50 day simple moving average is $49.58 and its 200 day simple moving average is $52.36.

GSK (NYSE:GSK) last released its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.47 EPS. On average, analysts predict that GSK will post 4.78 EPS for the current year.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.